Advertisement

Current Practices in the Treatment of Alzheimer Disease: Where is the Evidence After the Phase III Trials?

      Abstract

      Purpose

      The purpose of this systematic review was to review the current place in therapy of the 4 medications, donepezil, rivastigmine, galantamine, and memantine, approved for the treatment of Alzheimer disease (AD) since the publication of Phase III trials.

      Methods

      A systematic literature search of MEDLINE and EMBASE was conducted for articles published in the past 10 years. The search was performed using the following Medical Subject Headings and text key words: Alzheimer’s disease, treatment, donepezil, galantamine, rivastigmine, memantine, dementia of the Alzheimer’s type, and dementia.

      Findings

      Studies that evaluated new doses, indications, and dose formulations remain a large part of the current literature. Donepezil gained approval for the treatment of severe AD and became available in a 23-mg/d dose formulation. Rivastigmine became available in a patch formulation. Memantine became available as an extended-release capsule. Use of a combination product formulation was recently approved, memantine extended release/donepezil. Controversy among clinicians remains regarding when to initiate therapy, appropriate duration of therapy, and how and when to discontinue the treatment of AD.

      Implications

      Only drugs that affect cholinergic function have shown consistent, but modest, clinical effects, even in late-phase trials. There is a need for a better appreciation of the various risk factors and drug targets for the treatment of AD. The wide range of targets makes it unlikely that affecting only 1 of those targets (eg, cholinergic function or N-methyl-d-aspartate) will lead to a more than minimally effective treatment option, regardless of when a treatment is started and discontinued. There is substantial opportunity for the continued growth and development of drugs and clinical trial expansion for the treatment of AD.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Alzheimer’s Association
        Alzheimer’s disease facts and figures.
        Alzheimers Dement. 2012; 8: 131-168
        • Reitz C.
        • Brayne C.
        • Mayeux R.
        Epidemiology of Alzheimer disease.
        Nat Rev Neurol. 2011; 7: 137-152
        • Herholz K.
        • Carter S.F.
        • Jones M.
        Positron emission tomography imaging in dementia.
        Br J Radiol. 2007; 80: S160-S167
        • Iyo M.
        • Namba H.
        • Fukushi K.
        • et al.
        Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer’s disease.
        Lancet. 1997; 349: 1805-1809
        • Bohnen N.I.
        • Kauger D.I.
        • Henderickson R.
        • et al.
        Cognitive correlates of alterations in acetylcholinesterase in Alzheimer’s disease.
        Neurosci Lett. 2005; 380: 127-132
        • Morrison J.H.
        • Hof P.R.
        Life and death of neurons in the aging brain.
        Science. 1997; 278: 412-419
        • Wakabayashi K.
        • Nariswa-Saito M.
        • Iwakura Y.
        • et al.
        Phenotypic downregulation of glutamate receptor subunit GluR1 in Alzheimer’s disease.
        Neurobiol Aging. 1999; 20: 287-295
        • Francis P.T.
        • Parsons C.G.
        • Jones R.W.
        Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer’s disease.
        Expert Rev Neurother. 2012; 12: 1351-1365
      1. Aricept (donepezil hydrochloride) [package insert]. Teaneck, NJ: Eisai, Revised 2013

      2. Exelon (rivastigmine tartrate) [package insert]. East Hanover, NJ: Novartis, Revised 2013

      3. Razadyne ER/Razadyne (galantamine hydrobromine) [package insert]. Titusville, NJ: Ortho-McNeil Neurologics, Revised 2013

      4. Namenda (memantine hydrochloride) [package insert]. St. Louis, MO: Forest Pharmaceutica, Inc, Revised 2013.

        • Namenda X.R.
        (memantine hydrochloride) [package insert]. St. Louis, MO: Forest Pharmaceutica, Inc.
        Revised. 2013;
      5. Actavis and Adamas Announce FDA Approval of Namzaric, a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride. http://www.actavis.com/news/news/thomson-reuters/actavis-and-adamas-announce-fda-approval-of-namzar. Accessed March 22, 2015.

        • Smith A.
        • Kobayashi K.
        • Chappell N.
        • et al.
        The controversial promises of cholinesterase inhibitors for Alzheimer’s disease and related dementias: a qualitative study of caregivers’ experiences.
        J Aging Stud. 2011; 25: 397-406
        • Finucane T.E.
        Another advertisement for donepezil.
        J Am Geriatr Soc. 2004; 52: 843
        • Royall D.R.
        Donepezil’s effects remain uncertain.
        J Am Geriatr Soc. 2004; 52: 843-845
        • Karawish J.H.
        Donepezil delay to nursing home placement study is flawed.
        J Am Geriatr Soc. 2004; 52: 845
        • Schneider L.S.
        Open-label extension studies and misinformation.
        Arch Neurol. 2006; 63: 1036
        • Schneider L.S.
        Could cholinesterase inhibitors be harmful over the long term?.
        Int Psychogeriatr. 2012; 24: 171-174
        • Jadad A.R.
        • Moore R.A.
        • Carroll D.
        • et al.
        Assessing the quality of reports of randomized clinical trials: is blinding necessary?.
        Controlled Clin Trials. 1996; 17: 1-12
        • Mohs R.C.
        • Doody R.S.
        • Morris J.C.
        • et al.
        A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients.
        Neurology. 2001; 57: 481-488
        • Winblad B.
        • Engedal K.
        • Soininen H.
        • et al.
        A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.
        Neurology. 2001; 57: 489-495
        • Courtney C.
        • Farrell D.
        • Gray R.
        • et al.
        Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomized double-blind trial.
        Lancet. 2004; 363: 2105-2115
        • Suh G.-H.
        • Jung H.Y.
        • Lee C.U.
        • et al.
        for the Korean Galantamine Study Group. Economic and clinical benefits of galantamine in the treatment of mild to moderate Alzheimer’s disease in a Korean population: a 52-week prospective study.
        J Korean Med Sci. 2008; 23: 10-17
        • Hogan D.B.
        Long-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer disease.
        Can J Psychiatry. 2014; 59: 618-623
        • Winblad B.
        • Kilander L.
        • Eriksson S.
        • Minthon L.
        • Batsman S.
        • Wetterholm A.L.
        • et al.
        Donepezil in patients with severe Alzheimer’s disease: double-blind, parallel-group, placebo-controlled study.
        Lancet. 2006; 367: 1057-1065
        • Farlow M.R.
        • Salloway S.
        • Tariot P.N.
        • et al.
        Effectiveness and tolerability of high-dose (23 mg/d) versus standard dose (10 mg/d) donepezil in moderate to severe Alzheimer’s disease: a 24-week, randomized, double-blind study.
        Clin Ther. 2010; 32: 1234-1251
        • Sabbagh M.
        • Cummings J.
        • Christensen D.
        • et al.
        Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer’s disease: analysis of effects of baseline features on treatment response.
        BMC Geriatr. 2013; 13: 56
        • Doody R.S.
        • Geldmacher D.S.
        • Farlow M.
        • et al.
        Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer’s disease: a subgroup analysis in patients already taking or not taking concomitant memantine.
        Dement Geriatr Cogn Disord. 2012; 33: 164-173
        • Farlow M.R.
        • Grossberg G.T.
        • Sadowsky C.H.
        • et al.
        A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer’s dementia.
        CNS Neurosci Ther. 2013; 19: 745-752
        • Burns A.
        • Bernabei R.
        • Bullock R.
        • Cruz Jentoft A.J.
        • et al.
        Safety and efficacy of galantamine (Reminyl) in severe Alzheimer’s disease (the SERAD study): a randomised, placebo-controlled, double-blind trial.
        Lancet Neurol. 2009; 8: 39-47
        • Scarpini E.
        • Bruno G.
        • Zappala G.
        • et al.
        Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer’s disease: a randomized, double blind, placebo controlled withdrawal trial.
        J Alzheimer’s Dis. 2011; 26: 211-220
        • Grossberg G.T.
        • Manes F.
        • Allegri F.
        • et al.
        The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer’s disease taking cholinesterase inhibitors.
        CNS Drugs. 2013; 27: 469-478
        • Howard R.
        • McShane R.
        • Lindesay J.
        • et al.
        Donepezil and memantine for moderate-to-severe Alzheimer’s disease.
        N Engl J Med. 2012; 366: 893-903
      6. Center for Drug Evaluation and Research, US Food and Drug Administration. Sustained Release Aricept in Administrative Documents & Correspondence 02256Orig1s000Admincorres.pdf [memorandum of meeting minutes, March 19, 2007, IND 35,974]. www.accessdata.fda.gov/drugsatfda_doc/nda/2010/02256Orig1s000Admincorres.pdf. Accessed April 15, 2015.

        • Christensen D.D.
        Higher dose (23mg/day) donepezil formulation for the treatment of patients with moderate-to-severe Alzheimer’s disease.
        Postgrad Med. 2012; 124: 110-126
        • Tariot P.N.
        • Farlow M.R.
        • Grossberg G.T.
        • et al.
        for the Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial.
        JAMA. 2004; 291: 317-324
        • Farlow M.
        • Veloso F.
        • Moline M.
        • et al.
        Tolerability of donepezil 23 mg in moderate to severe Alzheimer’s Disease.
        BMC Neurol. 2011; 11: 57
      7. Aricept 23 mg tablets: summary review [FDA Center for Drug Evaluation and Research Application number 022568]. www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000SumR.pdf. Accessed April 15, 2015

        • Roberts J.S.
        • Karlawish J.H.
        • Uhlmann W.R.
        • et al.
        Mild cognitive impairment in clinical care: a survey of American Academy of Neurology members.
        Neurology. 2010; 75 (525–431)
        • Peters O.
        • Lorenz D.
        • Fesche A.
        • et al.
        A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI.
        J Nutr Health Aging. 2012; 16: 544-548
        • Petersen R.C.
        • Thomas R.G.
        • Grunchman M.
        • et al.
        Vitamin E and donepezil for the treatment of mild cognitive impairment.
        N Engl J Med. 2005; 352: 2379-2388
      8. National Institute for Health and Clinical Excellence. Donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s disease. NICE technology appraisal guidance 217, 2011. http://guidance.nice.org.uk/TA217. Accessed April 15, 2015.

        • Doody R.S.
        • Stevens J.C.
        • Beck C.
        • et al.
        Practice parameter: management of dementia (an evidence-based review).
        Neurology. 2001; 56: 1154-1166
        • Sadowsky C.H.
        • Galvin J.E.
        Guidelines for the management of cognitive and behavioral problems in dementia.
        J Am Board Fam Med. 2012; 25: 350-366
        • Farlow M.R.
        • Miller M.L.
        • Pejovic V.
        Treatment options in Alzheimer’s disease: maximizing benefit, managing expectations.
        Dement Geriatr Cogn Disord. 2008; 25: 408-422
        • Massoud F.
        • Desmarais J.E.
        • Gautheir S.
        Switching cholinesterase inhibitors in older adults with dementia.
        Int Psychogeriatr. 2011; 23: 372-378
        • Farlow M.R.
        • Cummings J.L.
        Effective pharmacologic management of Alzheimer’s disease.
        Am J Med. 2007; 120: 388-397
        • Rogers S.L.
        • Doody R.S.
        • Pratt R.D.
        • et al.
        Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: final analysis of a US multicentre open-label study.
        Eur Neuropsychopharmacol. 2000; 10: 195-203
        • Raskind M.A.
        • Peskind E.R.
        • Truyen L.
        • et al.
        The cognitive benefits of galantamine are sustained for at least 36 months: A long-term extension trial.
        Arch Neurol. 2004; 61: 252-256
        • Farlow M.R.
        • Lilly M.L.
        ENA713 B352 Study Group. Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer’s disease for up to 5 years.
        BMC Geriatr. 2005; 5: 3
        • Reisberg B.
        • Doody R.
        • Stoffler A.
        • et al.
        A 24-week open-label extension study of memantine in moderate to severe Alzheimer’s disease.
        Arch Neurol. 2006; 63: 49-54
        • Doody R.S.
        • Geldmacher D.S.
        • Gordon B.
        • et al.
        Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease.
        Arch Neurol. 2001; 58: 427-433
      9. Discontinuation of cholinesterase inhibitors for the treatment of severe Alzheimer’s disease. [ClinicalTrials.gov; updated Jan 13, 2014]. http://clinicaltrials.gov/show/NCT02035982. Accessed March 19, 2015.

        • Herrmann N.
        • Lanctot K.L.
        • Hogan D.B.
        Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012.
        Alzheimer Res Ther. 2013; 5: S5
        • Herrmann N.
        • Fillit H.M.
        • Doody R.S.
        • et al.
        2013; Recommendations for best practices in the treatment of Alzheimer’s disease in managed care.
        Am J Geriatr Pharmacother. 2006; 4: S9-S24
        • Ihl R.
        • Frolich L.
        • Winblad B.
        • et al.
        World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer’s disease and other dementias.
        World J Biol Psychiatry. 2011; 12: 2-32